Hartmut Goldschmidt

1 month ago | nature.com | Philippe Moreau |Katja Weisel |Hartmut Goldschmidt |Saad Usmani |Robert Orlowski |Nizar Bahlis | +7 more

AbstractIn the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years).

Dec 4, 2024 | nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more

AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.

Sep 25, 2024 | nature.com | Maria-Victoria Mateos |Katja Weisel |Valerio De Stefano |Hartmut Goldschmidt |Laure Vincent |Aurore Perrot | +2 more

AbstractTreatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1–35.0). Patients (N  =  248) had received median 4 prior LOT (range, 2–13) at enrollment.

Aug 4, 2024 | nature.com | Molly Went |Gísli H. Halldórsson |Andrea Gunnell |Philip J Law |Amit Sud |Gudmar Thorleifsson | +24 more

AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel.